45 related articles for article (PubMed ID: 36260984)
21. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
[TBL] [Abstract][Full Text] [Related]
22. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
23. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003
[TBL] [Abstract][Full Text] [Related]
24. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ; Maurer DM; O'Hara MH; O'Reilly EM; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Yu JX; Pfeiffer SM; Spasic M; Xu J; Gherardini PF; Karakunnel J; Mick R; Alanio C; Byrne KT; Hollmann TJ; Moore JS; Jones DD; Tognetti M; Chen RO; Yang X; Salvador L; Wherry EJ; Dugan U; O'Donnell-Tormey J; Butterfield LH; Hubbard-Lucey VM; Ibrahim R; Fairchild J; Bucktrout S; LaVallee TM; Vonderheide RH
Nat Med; 2022 Jun; 28(6):1167-1177. PubMed ID: 35662283
[TBL] [Abstract][Full Text] [Related]
25. T-Cell Immunotherapy against Mutant KRAS for Pancreatic Cancer.
Melief CJM
N Engl J Med; 2022 Jun; 386(22):2143-2144. PubMed ID: 35648709
[No Abstract] [Full Text] [Related]
26. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.
Leidner R; Sanjuan Silva N; Huang H; Sprott D; Zheng C; Shih YP; Leung A; Payne R; Sutcliffe K; Cramer J; Rosenberg SA; Fox BA; Urba WJ; Tran E
N Engl J Med; 2022 Jun; 386(22):2112-2119. PubMed ID: 35648703
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Inhibitors in Cancer Therapy.
Shiravand Y; Khodadadi F; Kashani SMA; Hosseini-Fard SR; Hosseini S; Sadeghirad H; Ladwa R; O'Byrne K; Kulasinghe A
Curr Oncol; 2022 Apr; 29(5):3044-3060. PubMed ID: 35621637
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic Cancer: A Review.
Park W; Chawla A; O'Reilly EM
JAMA; 2021 Sep; 326(9):851-862. PubMed ID: 34547082
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitors in melanoma.
Carlino MS; Larkin J; Long GV
Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
[TBL] [Abstract][Full Text] [Related]
30. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
[TBL] [Abstract][Full Text] [Related]
31. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.
Ho WJ; Jaffee EM; Zheng L
Nat Rev Clin Oncol; 2020 Sep; 17(9):527-540. PubMed ID: 32398706
[TBL] [Abstract][Full Text] [Related]
32. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Winograd R; Byrne KT; Evans RA; Odorizzi PM; Meyer AR; Bajor DL; Clendenin C; Stanger BZ; Furth EE; Wherry EJ; Vonderheide RH
Cancer Immunol Res; 2015 Apr; 3(4):399-411. PubMed ID: 25678581
[TBL] [Abstract][Full Text] [Related]
33. Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
Melief CJM
Cell Rep Med; 2022 Oct; 3(10):100788. PubMed ID: 36260984
[TBL] [Abstract][Full Text] [Related]
34. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]